艾沙康唑治疗真菌感染：来自瑞士真菌感染网络（FUNGINOS）的真实经验
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
作者信息
Couchepin Jade, Reinhold Ilana, Kronig Ilona, Guidi Monia, Buclin Thierry, Schreiber Peter W, Neofytos Dionysios, Lamoth Frederic
机构信息
Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.
出版信息
Open Forum Infect Dis. 2024 Apr 26;11(5):ofae223. doi: 10.1093/ofid/ofae223. eCollection 2024 May.
Abstract
This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.
摘要
对116个艾沙康唑治疗疗程的分析表明，肝脏检查异常（HTDs）相对常见（占病例的29%），但很少导致治疗中断（5%）。重要的是，基线存在HTDs的患者，包括那些归因于一线三唑类药物的患者，在接受艾沙康唑治疗时，后续发生HTD的风险并未更高。
相似文献
1
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).艾沙康唑治疗真菌感染：来自瑞士真菌感染网络（FUNGINOS）的真实经验
Open Forum Infect Dis. 2024 Apr 26;11(5):ofae223. doi: 10.1093/ofid/ofae223. eCollection 2024 May.
2
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.聚焦于艾沙康唑治疗侵袭性曲霉病和毛霉病：设计、研发及在治疗中的地位
Drug Des Devel Ther. 2018 Apr 30;12:1033-1044. doi: 10.2147/DDDT.S145545. eCollection 2018.
3
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.伊曲康唑：一种新型广谱三唑类抗真菌药物。
Clin Infect Dis. 2015 Nov 15;61(10):1558-65. doi: 10.1093/cid/civ571. Epub 2015 Jul 15.
4
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.伊曲康唑治疗毛霉病：一项单臂开放标签试验和病例对照分析。
Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.
5
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.瑞典伊曲康唑与伏立康唑治疗疑似侵袭性曲霉病患者的成本效果分析。
BMC Infect Dis. 2019 Feb 11;19(1):134. doi: 10.1186/s12879-019-3683-2.
6
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.艾沙康唑治疗实体器官移植受者侵袭性霉菌病：真实临床实践中疗效与安全性的多中心研究
Transplantation. 2023 Mar 1;107(3):762-773. doi: 10.1097/TP.0000000000004312. Epub 2022 Oct 20.
7
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.伊曲康唑：一种新型广谱唑类药物。第 2 部分：药代动力学和临床活性。
J Mycol Med. 2018 Mar;28(1):15-22. doi: 10.1016/j.mycmed.2018.02.002. Epub 2018 Mar 16.
8
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).固体器官移植受者真菌感染伊曲康唑治疗的安全性和有效性（ISASOT 研究）。
Microbiol Spectr. 2022 Feb 23;10(1):e0178421. doi: 10.1128/spectrum.01784-21. Epub 2022 Feb 16.
9
Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study.比较在有和没有潜在差异的患者中，伊曲康唑与其他抗真菌疗法在侵袭性真菌感染的真实世界使用情况：一项多中心回顾性研究。
J Fungi (Basel). 2023 Jan 27;9(2):166. doi: 10.3390/jof9020166.
10
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.日本一项 3 期、随机、开放标签研究：伊曲康唑治疗深部真菌感染的疗效和安全性。
J Infect Chemother. 2023 Feb;29(2):163-170. doi: 10.1016/j.jiac.2022.10.010. Epub 2022 Oct 25.
引用本文的文献
1
TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients.基于治疗药物监测的方法在重症患者复杂病例组合中合理管理静脉注射艾沙康唑治疗
Antibiotics (Basel). 2025 Aug 1;14(8):777. doi: 10.3390/antibiotics14080777.
2
Real-World Experience with Isavuconazole for Invasive Aspergillosis in Hematologic Patients with and Without COVID-19 in Brazil.在巴西，接受和未感染新冠病毒的血液病患者使用艾沙康唑治疗侵袭性曲霉病的真实世界经验。
J Fungi (Basel). 2025 Jun 16;11(6):456. doi: 10.3390/jof11060456.
3
Reply to Martin-Loeches and Rodriguez: Clinical Guidelines: Asking the Right Questions to Guide Fungal Infection Management.致马丁 - 勒切斯和罗德里格斯的回复：临床指南：提出正确问题以指导真菌感染管理
Am J Respir Crit Care Med. 2025 Jun;211(6):1097-1098. doi: 10.1164/rccm.202501-0152LE.
4
An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of Indications, Exposure and Hepatic Safety.艾沙康唑临床应用概述：适应症、暴露情况及肝脏安全性的多中心分析
Clin Drug Investig. 2025 May;45(5):271-282. doi: 10.1007/s40261-025-01432-z. Epub 2025 Mar 28.
5
Invasive fungal infections in patients with liver disease: immunological and clinical considerations for the intensive care unit.肝病患者的侵袭性真菌感染：重症监护病房的免疫学和临床考量
Intensive Care Med. 2025 Feb;51(2):364-377. doi: 10.1007/s00134-025-07797-1. Epub 2025 Feb 17.
本文引用的文献
1
Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.伊曲康唑治疗实体器官移植受者侵袭性霉菌病。
Transpl Int. 2023 Dec 15;36:11845. doi: 10.3389/ti.2023.11845. eCollection 2023.
2
A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.一项关于伊曲康唑治疗和预防侵袭性真菌感染的疗效和安全性的系统评价和荟萃分析。
Mycoses. 2023 Sep;66(9):815-824. doi: 10.1111/myc.13622. Epub 2023 Jun 10.
3
Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study.在艾沙康唑治疗下的起始和演变情况：一项为期两年的前瞻性真实世界研究
Med Mycol. 2023 Apr 3;61(4). doi: 10.1093/mmy/myad033.
4
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.与泊沙康唑和伏立康唑相比，艾沙康唑预防突破性真菌感染的发生率。
Transpl Infect Dis. 2023 Apr;25(2):e14045. doi: 10.1111/tid.14045. Epub 2023 Mar 1.
5
Pulmonary aspergillosis: diagnosis and treatment.肺曲霉病：诊断与治疗。
Eur Respir Rev. 2022 Nov 29;31(166). doi: 10.1183/16000617.0114-2022. Print 2022 Dec 31.
6
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.艾沙康唑治疗实体器官移植受者侵袭性霉菌病：真实临床实践中疗效与安全性的多中心研究
Transplantation. 2023 Mar 1;107(3):762-773. doi: 10.1097/TP.0000000000004312. Epub 2022 Oct 20.
7
Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease.伊曲康唑作为慢性肺真菌病挽救治疗的经验
J Fungi (Basel). 2022 Mar 31;8(4):362. doi: 10.3390/jof8040362.
8
Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience.伊曲康唑在高危血液病患者中的临床应用：单中心 5 年经验。
Mycopathologia. 2021 Dec;186(6):775-788. doi: 10.1007/s11046-021-00583-9. Epub 2021 Aug 25.
9
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.伊曲康唑与伏立康唑作为异基因造血细胞移植受者一线抗真菌预防治疗的疗效和安全性比较。
Med Mycol. 2021 Oct 4;59(10):970-979. doi: 10.1093/mmy/myab025.
10
Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.伊曲康唑预防肺移植受者真菌感染的疗效与伏立康唑相当，且耐受性更好。
Clin Infect Dis. 2021 Aug 2;73(3):416-426. doi: 10.1093/cid/ciaa652.
Zotero 插件